Afatinib Dimaleate CAS 850140-73-7 Purity >99.5% (HPLC) API
Ruifu Chemical Supply Intermediates of Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino)acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4 (1H)-e le 'ngoe CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Lebitso la Lik'hemik'hale | Afatinib Dimaleate |
Litlhaloso tse tšoanang | BIBW2992 Dimaleate;(S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-Enamide Dimaleate |
Nomoro ea CAS | 618-89-3 |
Nomoro ea KAtse | RF-PI2032 |
Boemo ba Setoko | Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane |
Foromo ea limolek'hule | C32H33ClFN5O11 |
Boima ba Molek'hule | 718.08 |
Kutloisiso | E Mamela Mongobo |
Brand | Ruifu Chemical |
Ntho | Litlhaloso |
Ponahalo | Phofo e tšoeu ho isa ho e tšoeu |
Mokhoa oa Bohloeki / Analysis | >99.5% (HPLC) |
Tahlehelo ka ho Omisa | <0.50% |
Masalla a ho Ignition | <0.10% |
Ho se hloeke ho hoholo ho le Mong | <0.30% |
Litšila ka Kakaretso | <0.50% |
Heavy Metals (as Pb) | ≤20ppm |
Infrared Spectrum | E Ikamahanya le Sebopeho |
NMR | E Ikamahanya le Sebopeho |
Tekanyetso ea Teko | Maemo a Khoebo |
Shelf Life | Likhoeli tse 24 Haeba li Behiloe Hantle |
Tšebeliso | API |
Sephutheloana: Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo
Afatinib Dimaleate (CAS: 850140-73-7), mofuta oa letsoai oa dimaleate oa afanitib, ke moemeli oa antineoplastic o fumanehang ka molomo.Afatinib Dimaleate ke EGFR family inhibitor e ke keng ea fetoloa e nang le IC50s ea 0.5 nM, 0.4 nM, 10 nM le 14 nM bakeng sa EGFRwt, EGFRL858R, EGFRL858R/T790M le HER2, ka ho latellana.Afatinib Dimaleate e bontšoa bakeng sa kalafo ea pele ea bakuli ba nang le mofetše oa metastatic o seng o monyane oa lisele tsa matšoafo (NSCLC) bao lihlahala tsa bona li nang le li-epidermal growth factor receptor (EGFR) exon 19 deletions kapa exon 21 (L858R) tse fetotsoeng ke FDA- teko e amohelehang.Nakong e fetileng, phekolo e tloaelehileng ka polatinamo ea chemotherapy doublet regimen e ne e nkoa e le phekolo e tloaelehileng ea pele bakeng sa bakuli bohle ba NSCLC.Leha ho le joalo, bopaki bo hlahang bo khethile batho ba fokolang bao ho bona phekolo e lebisitsoeng e sebetsang haholoanyane, e lebisang ho nts'etsopele ea lithethefatsi tse khethehileng tsa phetoho.Afatinib Dimaleate e thehiloe ke Boehringer Ingelheim Pharmaceuticals, Afatinib Dimaleate e amohetsoe ke FDA ka 2013 joalo ka setlhare sa likhutsana tlasa lebitso la khoebo la Gilotrif.Afatinib Dimaleate e entsoe ka lik'hemik'hale ho sebelisoa mekhoa e tloaelehileng.Afatinib Dimaleateha e sebetse feela khahlanong le liphetoho tsa EGFR tse lebisitsoeng ke TKI ea moloko oa pele joaloka erlotinib kapa gefitinib, empa hape le khahlanong le liphetoho tse kang T790M tse sa tsotelleng mekhoa ena ea phekolo e tloaelehileng.Ka lebaka la ts'ebetso ea eona e eketsehileng khahlano le Her2, e ntse e batlisisoa bakeng sa mofetše oa matsoele hammoho le mefuta e meng ea mofets'e oa EGFR le Her2.